Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma. (Funded by an unrestricted educational grant from F. Hoffmann–La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939; Eudra-CT number, 2010-023218-30.)

中文翻译：

---

炎性肠病和NLRP3炎性小体

尽管在某种程度上延长了无进展生存期，但在进行性胶质母细胞瘤患者中，洛莫司汀联合贝伐单抗治疗并没有比洛莫司汀单独治疗具有生存优势。（由F. Hoffmann-La Roche和EORTC癌症研究基金提供无限制的教育资助； EORTC 26101 ClinicalTrials.gov号，NCT01290939； Eudra-CT号，2010-023218-30。）